Obinutuzumab: first global approval

Drugs
Fiona Cameron, Paul L McCormack

Abstract

Obinutuzumab (Gazyva™) is an intravenously administered, humanized and glycoengineered, type II anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. It is approved in the US for use in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukaemia (CLL), and has been filed for approval in the EU in this indication. The antibody is based on GlycArt Biotechnology's (later Roche Glycart AG) proprietary GlycoMAb® technology, which uses glycoengineered antibodies that specifically increase antibody-dependent cellular cytotoxicity and thereby increase immune-mediated target cell death. Obinutuzumab is a type II anti-CD20 antibody that induces enhanced direct cell death. The monoclonal antibody is in worldwide phase III development with Roche and its subsidiaries, Genentech and Chugai Pharmaceutical, as well as Biogen Idec, for diffuse large B-cell lymphoma and non-Hodgkin's lymphoma generally, and is also in phase III development in countries outside of the US and EU for CLL.

References

Oct 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yuki MoritokiM Eric Gershwin
Nov 17, 2011·Drugs·Julie E Chang, Brad S Kahl
Sep 11, 2012·Current Opinion in Oncology·Till M Seiler, Wolfgang Hiddemann
Feb 19, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sarwish RafiqJohn C Byrd
Apr 24, 2013·Therapeutic Advances in Hematology·Michele MerliFrancesco Passamonti
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gilles A SallesGuillaume Cartron
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck Andre MorschhauserGilles Andre Salles
Mar 7, 2014·Current Opinion in Biotechnology·Mattheos A G Koffas, Jan Marienhagen

❮ Previous
Next ❯

Citations

Sep 5, 2014·Drugs·Anthony Markham
Jul 15, 2015·Expert Opinion on Emerging Drugs·Pawel RobakTadeusz Robak
Dec 1, 2015·Future Oncology·Craig ErkerMichael J Burke
Dec 20, 2014·Future Oncology·Abdulmunem AbulayhaIan Daniels
Jul 5, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Minoru Tada, Akiko Ishii-Watabe
Oct 6, 2018·Glycobiology·Renato MastrangeliHorst Bierau
May 4, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Xiaojie YuMax Crispin
Aug 26, 2021·Expert Opinion on Biological Therapy·Anurag Rathore, Himanshu Malani
Nov 5, 2021·Frontiers in Immunology·Kristina Zlatina, Sebastian P Galuska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.